NCIt related terms : Lenalidomide and Rituximab (R2); Lenalidomide and Rituximab-arrx (R2); Lenalidomide and Rituximab-rixi (R2); Lenalidomide and Rituximab-pvvr (R2); Lenalidomide and Rituximab-rite (R2); Lenalidomide and Rituximab-abbs (R2); Lenalidomide and Rituximab-blit (R2); Lenalidomide and Rituximab-rixa (R2);
NCIt definition : A regimen consisting of lenalidomide and rituximab that can be used in the treatment
of primary central nervous system (CNS) lymphoma, Castleman disease, and non-Hodgkin
lymphoma, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma
(SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma,
gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, and nodal
and splenic marginal zone lymphoma.;